Skip to main content

Table 4 Correlation analysis of SCC antigen levels with overall survival of patients with cervical squamous cell carcinoma

From: Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma

Variable Mean survival times (months) χ2 P
SCC antigen levels before chemotherapy   0.095 0.758
 NACT group (n = 63) 40.16 (37.24, 43.07)   
 Conventional group (n = 39) 33.43 (31.31, 35.56)   
NACT group   0.098 0.754
 Chemotherapy-insensitive group (n = 32) 41.19 (37.29, 45.08)   
 Chemotherapy-sensitive group (n = 31) 39.25 (35.01, 43.50)   
SCC antigen levels in NACT group before chemotherapy   9.880 0.002
  < 4.55 (n = 29) NA a   
  ≥ 4.55 (n = 34) NA a   
SCC antigen levels ≥4.55 before chemotherapy   4.176 0.041
 NACT group (n = 34) 36.40 (31.59, 41.22)   
 Conventional group (n = 21) 32.95 (30.95, 34.96)   
SCC antigen levels in NACT group after the first chemotherapy   10.869 0.001
  < 2.70 (n = 39) 43.75 (42.07, 45.43)   
  ≥ 2.70 (n = 24) 34.40 (28.99, 40.81)   
  1. a, in NACT group before chemotherapy, when SCC antigen levels < 4.55 ng/mL, 29 patients were survival and it is impossible to calculate the survival times of patients